News

NU172 is an aptamer designed to directly inhibit thrombin’s ability to stimulate blood clot formation in the setting of medical procedures where human blood is exposed to foreign

Radius plans to begin a Phase I clinical trial of RAD1901 in healthy postmenopausal women in the Netherlands in March 2008. The study will evaluate the safety, tolerability,

Under the terms of the agreement, Harvard has granted Millennium a license to certain invention from the laboratory of Wade Harper and the two institutions will jointly advance

The study results indicated that among the animals treated with the APA-01 and atorvastatin combination, total cholesterol levels fell by up to an additional 12% compared to those

The underwriters have an option to purchase up to an additional 750,000 shares to cover over-allotments, if any. The offering is expected to close on February 6, 2008,

The company has developed two unique supplement lines and is developing treatments for diseases. The new Cavit facility is significantly larger than the company’s previous space and accommodates

This latest Phase II trial is an international, multi-center, double-blind and placebo-controlled study of SA4503 in patients with stroke with a planned enrollment of approximately 60 patients. The

The investment syndicate includes new investors Goldman Sachs and Invesco Perpetual, as well as existing investors, including Imperial Innovations and Lansdowne Partners. This second investment round has increased

The transaction involved a total capital investment of $74.6 million, in cash paid to Guangzhou Pharmaceuticals (GP Corp.) in exchange for a 50% ownership interest in GP Corp.